Difference between revisions of "Bone sarcoma"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[[Category:Sarcoma" to "[[Category:Soft tissue sarcoma")
m (Text replacement - "[[Category:Bone cancer" to "[[Category:Bone sarcoma")
Line 60: Line 60:
 
*Please see the [[osteosarcoma|dedicated osteosarcoma page]].
 
*Please see the [[osteosarcoma|dedicated osteosarcoma page]].
  
[[Category:Bone cancer regimens]]
+
[[Category:Bone sarcoma regimens]]
 
[[Category:Disease-specific pages]]
 
[[Category:Disease-specific pages]]
 
[[Category:Soft tissue sarcomas]]
 
[[Category:Soft tissue sarcomas]]

Revision as of 03:26, 24 October 2017

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

0 regimens on this page
0 variants on this page


Note: this page is a gathering place for the 10+ subtypes of bone sarcoma. Subtypes with substantial numbers of regimens will be moved to their own pages, with links preserved here.

Guidelines

ESMO

NCCN

Chondrosarcoma, all lines of therapy

Ewing's sarcoma, all lines of therapy

Giant-cell tumor of bone, all lines of therapy

Denosumab monotherapy

back to top

Regimen

Study Evidence
Thomas et. al 2010 Phase II

Primary therapy

  • Denosumab (Xgeva) as follows:
    • Cycle 1: 120 mg SC once per day on days 1, 8, 15
    • Cycle 2 onwards: 120 mg SC once on day 1

Supportive medications

  • Calcium 500 mg PO once per day
  • Vitamin D 400 IU PO once per day

28-day cycles, given until complete tumor resection, progression of disease, or patient choice

References

  1. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. link to original article contains verified protocol PubMed

Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy

Osteosarcoma, all lines of therapy